Item 2.02. Results of Operations and Financial Condition

On January 5, 2023, Marinus Pharmaceuticals, Inc. (the "Company") issued a press release announcing its preliminary net product revenue for the fourth quarter and the year ended December 31, 2022 and certain other information (the "Press Release"). The amounts included in the Press Release are preliminary, have not been audited and are subject to change upon completion of the Company's audited financial statements for the year ended December 31, 2022. Additional information and disclosures would be required for a more complete understanding of the Company's financial position and results of operations as of December 31, 2022. A copy of the Press Release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 8.01. Other Events.

On January 5, 2023, the Company issued the Press Release, a copy of which is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.



Exhibit
No.         Description
99.1          Press Release, dated January 5, 2023, of Marinus Pharmaceuticals,
            Inc.
104         The cover page from this Current Report on Form 8-K, formatted in
            Inline XBRL.

© Edgar Online, source Glimpses